H1B Report
Side-by-side comparison

INFOSYS LIMITED vs Regeneron Pharmaceuticals, Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
INFOSYS LIMITED
TXRank #1FEIN 58-1760235
Entity B
Regeneron Pharmaceuticals, Inc.
NYRank #FEIN 13-3444607

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricINFOSYS LIMITEDRegeneron Pharmaceuticals, Inc.
Total filings205,2631,166
Certified %99.55%97.17%
Denied %0.21%0.51%
Withdrawn %0.20%1.20%
Cert-withdrawn %0.05%1.11%
Rank#1
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateTXNY

Outcomes — INFOSYS LIMITED

DOL case-status mix.

Outcome breakdown: Certified 99.5%, Cert-withdrawn 0.0%, Withdrawn 0.2%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%
Certified99.5%
Cert-withdrawn0.0%
Withdrawn0.2%
Denied0.2%

Outcomes — Regeneron Pharmaceuticals, Inc.

DOL case-status mix.

Outcome breakdown: Certified 97.2%, Cert-withdrawn 1.1%, Withdrawn 1.2%, Denied 0.5%
Outcome breakdown
OutcomeShare
Certified97.2%
Cert-withdrawn1.1%
Withdrawn1.2%
Denied0.5%
Certified97.2%
Cert-withdrawn1.1%
Withdrawn1.2%
Denied0.5%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

INFOSYS LIMITED
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,164
FY20111,681
FY201214,701
FY201332,232
FY201423,749
FY201533,214
FY201625,335
FY201720,571
FY201811,569
FY201921,420
FY202016
FY202129
FY202222
FY20232,269
FY20245,943
FY20255,790
FY20264,558
Regeneron Pharmaceuticals, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201051
FY201137
FY201240
FY201344
FY201443
FY201539
FY201647
FY201762
FY201880
FY201999
FY202024
FY202119
FY202224
FY202342
FY2024130
FY2025159
FY2026226

Top 5 occupations — INFOSYS LIMITED

Top 5 occupations — Regeneron Pharmaceuticals, Inc.

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.